135 related articles for article (PubMed ID: 19863054)
1. Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage.
García G; Rodríguez-Puyol M; Alajarín R; Serrano I; Sánchez-Alonso P; Griera M; Vaquero JJ; Rodríguez-Puyol D; Alvarez-Builla J; Díez-Marqués ML
J Med Chem; 2009 Nov; 52(22):7220-7. PubMed ID: 19863054
[TBL] [Abstract][Full Text] [Related]
2. New losartan-hydrocaffeic acid hybrids as antihypertensive-antioxidant dual drugs: Ester, amide and amine linkers.
García G; Serrano I; Sánchez-Alonso P; Rodríguez-Puyol M; Alajarín R; Griera M; Vaquero JJ; Rodríguez-Puyol D; Alvarez-Builla J; Díez-Marqués ML
Eur J Med Chem; 2012 Apr; 50():90-101. PubMed ID: 22336384
[TBL] [Abstract][Full Text] [Related]
3. NO-sartans: a new class of pharmacodynamic hybrids as cardiovascular drugs.
Breschi MC; Calderone V; Digiacomo M; Martelli A; Martinotti E; Minutolo F; Rapposelli S; Balsamo A
J Med Chem; 2004 Nov; 47(23):5597-600. PubMed ID: 15509155
[TBL] [Abstract][Full Text] [Related]
4. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect.
Yao EH; Fukuda N; Matsumoto T; Kobayashi N; Katakawa M; Yamamoto C; Tsunemi A; Suzuki R; Ueno T; Matsumoto K
Hypertens Res; 2007 Nov; 30(11):1119-28. PubMed ID: 18250561
[TBL] [Abstract][Full Text] [Related]
5. Simply removing pressure doesn't work, but youthful drug-taking prevents hereditary mid-life failure.
McGrath JC
J Hypertens; 2007 Jan; 25(1):55-6. PubMed ID: 17143173
[No Abstract] [Full Text] [Related]
6. Supramolecular interactions between losartan and hydroxypropyl-β-CD: ESI mass-spectrometry, NMR techniques, phase solubility, isothermal titration calorimetry and anti-hypertensive studies.
de Paula WX; Denadai AM; Santoro MM; Braga AN; Santos RA; Sinisterra RD
Int J Pharm; 2011 Feb; 404(1-2):116-23. PubMed ID: 21093554
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of the combination of amlodipine and losartan for lowering blood pressure in spontaneously hypertensive rats.
Choi SM; Seo MJ; Kang KK; Kim JH; Ahn BO; Yoo M
Arch Pharm Res; 2009 Mar; 32(3):353-8. PubMed ID: 19387578
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II receptor blocker, losartan, ameliorates gentamicin-induced oxidative stress and nephrotoxicity in rats.
Heeba GH
Pharmacology; 2011; 87(3-4):232-40. PubMed ID: 21474976
[TBL] [Abstract][Full Text] [Related]
9. New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties.
Breschi MC; Calderone V; Digiacomo M; Macchia M; Martelli A; Martinotti E; Minutolo F; Rapposelli S; Rossello A; Testai L; Balsamo A
J Med Chem; 2006 Apr; 49(8):2628-39. PubMed ID: 16610806
[TBL] [Abstract][Full Text] [Related]
10. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats.
Izuhara Y; Sada T; Yanagisawa H; Koike H; Ohtomo S; Dan T; Ito S; Nangaku M; van Ypersele de Strihou C; Miyata T
Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1767-73. PubMed ID: 18658044
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II regulates cardiac hypertrophy via oxidative stress but not antioxidant enzyme activities in experimental renovascular hypertension.
Polizio AH; Balestrasse KB; Yannarelli GG; Noriega GO; Gorzalczany S; Taira C; Tomaro ML
Hypertens Res; 2008 Feb; 31(2):325-34. PubMed ID: 18360053
[TBL] [Abstract][Full Text] [Related]
12. Losartan exerts renoprotection through NAD(P)H oxidase downregulation in a renovascular model of hypertension.
Polizio AH; Balestrasse KB; Gornalusse GG; Gorzalczany SB; Santa-Cruz DM; Yannarelli GG; Peña C; Tomaro ML
Regul Pept; 2009 Aug; 156(1-3):28-33. PubMed ID: 19445972
[TBL] [Abstract][Full Text] [Related]
13. Losartan reduces oxidative damage to renal DNA and conserves plasma antioxidant capacity in diabetic rats.
Lodovici M; Bigagli E; Tarantini F; Di Serio C; Raimondi L
Exp Biol Med (Maywood); 2015 Nov; 240(11):1500-4. PubMed ID: 25710927
[TBL] [Abstract][Full Text] [Related]
14. A sartan derivative with a very low angiotensin II receptor affinity ameliorates ischemic cerebral damage.
Takizawa S; Dan T; Uesugi T; Nagata E; Takagi S; van Ypersele de Strihou C; Miyata T
J Cereb Blood Flow Metab; 2009 Oct; 29(10):1665-72. PubMed ID: 19536069
[TBL] [Abstract][Full Text] [Related]
15. Losartan: Comprehensive Profile.
Al-Majed AR; Assiri E; Khalil NY; Abdel-Aziz HA
Profiles Drug Subst Excip Relat Methodol; 2015; 40():159-94. PubMed ID: 26051686
[TBL] [Abstract][Full Text] [Related]
16. Changes in the composition of the thoracic aortic wall in spontaneously hypertensive rats treated with losartan or spironolactone.
Han WQ; Wu LY; Zhou HY; Zhang J; Che ZQ; Wu YJ; Liu JJ; Zhu DL; Gao PJ
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):583-8. PubMed ID: 19673944
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide.
Abe M; Okada K; Matsumoto K
Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1285-303. PubMed ID: 19761411
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular effects of losartan and its relevant clinical application.
Xu F; Mao C; Hu Y; Rui C; Xu Z; Zhang L
Curr Med Chem; 2009; 16(29):3841-57. PubMed ID: 19747137
[TBL] [Abstract][Full Text] [Related]
19. Direct action of an angiotensin II receptor blocker on angiotensin II-induced left atrial conduction delay in spontaneously hypertensive rats.
Matsuyama N; Tsutsumi T; Kubota N; Nakajima T; Suzuki H; Takeyama Y
Hypertens Res; 2009 Aug; 32(8):721-6. PubMed ID: 19590505
[TBL] [Abstract][Full Text] [Related]
20. Angiotensins II and IV modulate adrenocortical cell proliferation in ovariectomized rats.
Siejka A; Mełeń-Mucha G; Mucha SA; Pawlikowski M
J Physiol Pharmacol; 2006 Sep; 57(3):451-61. PubMed ID: 17033097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
